Kyverna Therapeutics (KYTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors, Ian Clark and Christi Shaw, to serve until the 2029 annual meeting.
Ratification of BDO USA, P.C. as independent auditor for the year ending December 31, 2026.
Proxies may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Audit Committee selected BDO USA, P.C. as the independent registered public accounting firm for 2026.
Shareholders are asked to ratify this appointment at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kyverna Therapeutics
- Strong clinical data and FDA alignment position for first CAR T launch in autoimmune diseases.KYTX
Jefferies Global Healthcare Conference 20263 Jun 2026 - Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and market potential.KYTX
Corporate presentation3 Jun 2026 - Director elections and auditor ratification approved as commercial and regulatory milestones advance.KYTX
AGM 202627 May 2026 - Transformative CAR-T therapy for SPS nears launch, with expansion into MG and MS underway.KYTX
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and scalability.KYTX
Investor presentation12 May 2026 - Rolling BLA for miv-cel in SPS underway, strong trial results, and solid cash position.KYTX
Q1 202612 May 2026 - Miv-cel achieved robust, durable efficacy and drug-free remission in SPS and gMG, supporting launch.KYTX
Status update22 Apr 2026 - Proposals include director elections and auditor ratification, with strong governance and ESG oversight.KYTX
Proxy filing13 Apr 2026 - Miv-cel demonstrates transformative efficacy in autoimmune diseases, targeting SPS and gMG first.KYTX
Corporate presentation26 Mar 2026